-
公开(公告)号:US08853281B2
公开(公告)日:2014-10-07
申请号:US13139962
申请日:2009-12-18
申请人: Susana Ayesa , Anna Karin Belfrage , Bjorn Classon , Urszula Grabowska , Ellen Hewitt , Vladimir Ivanov , Daniel Jönsson , Pia Kahnberg , Peter Lind , Magnus Nilsson , Lourdes Odén , Mikael Pelcman , Horst Wähling
发明人: Susana Ayesa , Anna Karin Belfrage , Bjorn Classon , Urszula Grabowska , Ellen Hewitt , Vladimir Ivanov , Daniel Jönsson , Pia Kahnberg , Peter Lind , Magnus Nilsson , Lourdes Odén , Mikael Pelcman , Horst Wähling
IPC分类号: A01N33/02 , A61K31/13 , A01N37/00 , A61K31/21 , A01N33/00 , A61K31/16 , A01N37/18 , A61K31/165 , A01N35/00 , A61K31/12 , A01N33/18 , A01N33/24 , A61K31/04 , A01N29/00 , A61K31/02 , A01N29/02 , C07D231/00 , C07D413/00 , C07D295/22 , C07D307/02 , C07C303/00 , C07C307/00 , C07C309/00 , C07C311/00 , C07C233/00 , C07C235/00 , C07C237/00 , C07C239/00 , C07C261/00 , C07C269/00 , C07C271/00 , C07D405/12 , C07D403/12 , C07C271/24 , C07D417/12 , C07C311/21 , C07D241/24 , C07D401/12 , C07D277/36 , C07D307/85 , C07D307/68 , C07D277/56 , C07D295/215 , C07C237/24 , C07D231/40 , C07D207/34 , C07D213/71 , C07D231/14 , C07D239/80 , C07D213/40
CPC分类号: C07C311/21 , C07C237/24 , C07C271/24 , C07C2601/02 , C07C2601/04 , C07C2601/06 , C07C2601/08 , C07D207/34 , C07D213/40 , C07D213/71 , C07D231/14 , C07D231/40 , C07D239/80 , C07D241/24 , C07D277/36 , C07D277/56 , C07D295/215 , C07D307/68 , C07D307/85 , C07D401/12 , C07D403/12 , C07D405/12 , C07D417/12
摘要: Compounds of the formula I wherein R1a is H; and R1b is C1-C6 alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are H, halo, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy; or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10alkyl chain, C2-C4haloalkyl or C3-C7cycloalkylmethyl, R4 is Het, Carbocyclyl, optionally substituted as defined in the specification and pharmaceutically acceptable salts, hydrates and N-oxides thereof; are inhibitors of cathepsin S and have utility in the treatment of psoriasis, autoimmune disorders and other disorders such as asthma, arteriosclerosis, COPD and chronic pain.
摘要翻译: 式Ⅰ化合物,其中R1a是H; 并且R 1b是C 1 -C 6烷基,碳环或Het; 或R 1a和R 1b一起限定具有3-6个环原子的饱和环胺; R2a和R2b是H,卤素,C1-C4烷基,C1-C4卤代烷基,C1-C4烷氧基; 或R 2a和R 2b与它们所连接的碳原子一起形成C 3 -C 6环烷基; R3是支链C 5 -C 10烷基链,C 2 -C 4卤代烷基或C 3 -C 7环烷基甲基,R 4是Het,碳环基,如说明书中所定义的任选取代,以及其药学上可接受的盐,水合物和N-氧化物; 是组织蛋白酶S的抑制剂,并且可用于治疗牛皮癣,自身免疫性疾病和其它疾病如哮喘,动脉硬化,COPD和慢性疼痛。
-
公开(公告)号:US08815809B2
公开(公告)日:2014-08-26
申请号:US13514758
申请日:2010-12-10
申请人: Susana Ayesa , Karolina Ersmark , Urszula Grabowska , Ellen Hewitt , Daniel Jönsson , Pia Kahnberg , Björn Klasson , Peter Lind , Stina Lundgren , Lourdes Odèn , Kevin Parkes , Daniel Wiktelius
发明人: Susana Ayesa , Karolina Ersmark , Urszula Grabowska , Ellen Hewitt , Daniel Jönsson , Pia Kahnberg , Björn Klasson , Peter Lind , Stina Lundgren , Lourdes Odèn , Kevin Parkes , Daniel Wiktelius
CPC分类号: C07K5/06078 , A61K38/05 , C07C271/22 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07D231/40 , C07D277/46 , C07D405/12 , C07K5/06034 , C07K5/0606 , C07K5/06139
摘要: Compounds of Formula II wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10 alkyl chain, C2-C4haloalkyl or —CH2C3-C7 cycloalkyl; R4′ is C1-C6alkyl, C1-C6haloalkyl or oxetany-3-yl. for use in the prophylaxis or treatment of a disorder characterized by inappropriate expression or activation of cathepsin S.
摘要翻译: 式II的化合物,其中R 1a是H; 并且R 1b是C 1 -C 6烷基,碳环或Het; 或R 1a和R 1b一起限定具有3-6个环原子的饱和环胺; R2a和R2b独立地为H,卤素,C1-C4烷基,C1-C4卤代烷基或C1-C4烷氧基,或R2a和R2b与它们所连接的碳原子一起形成C 3 -C 6环烷基; R3是支链C 5 -C 10烷基链,C 2 -C 4卤代烷基或-CH 2 C 3 -C 7环烷基; R 4'是C 1 -C 6烷基,C 1 -C 6卤代烷基或氧杂环丁烷-3-基。 用于预防或治疗以组织蛋白酶S不适当表达或活化为特征的病症。
-
公开(公告)号:US20120283305A1
公开(公告)日:2012-11-08
申请号:US13514760
申请日:2010-12-10
申请人: Susana Ayesa , Peter Carlqvist , Karolina Ersmark , Urszula Grabowska , Ellen Hewitt , Daniel Jönsson , Pia Kahnberg , Björn Klasson , Peter Lind , Lourdes Odén , Kevin Parkes , Daniel Wiktelius
发明人: Susana Ayesa , Peter Carlqvist , Karolina Ersmark , Urszula Grabowska , Ellen Hewitt , Daniel Jönsson , Pia Kahnberg , Björn Klasson , Peter Lind , Lourdes Odén , Kevin Parkes , Daniel Wiktelius
IPC分类号: A61K31/415 , C07C237/22 , A61K31/16 , A61P17/06 , A61P37/00 , A61P7/00 , A61P29/00 , A61P19/02 , A61P25/00 , A61P21/04 , A61P11/02 , A61P11/06 , A61P9/10 , A61P11/00 , C07D231/40
CPC分类号: C07K5/06078 , A61K38/05 , C07C271/22 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07D231/40 , C07D277/46 , C07D405/12 , C07K5/06034 , C07K5/0606 , C07K5/06139
摘要: Compounds of the formula I wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10 alkyl chain, C2-C4haloalkyl or —CH2C3-C7 cycloalkyl; R4 is C1-C6alkyl, C1-C6haloalkyl, C1-C6alkylamino or C1-C6dialkylamino; for use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.
摘要翻译: 式Ⅰ化合物,其中R1a是H; 并且R 1b是C 1 -C 6烷基,碳环或Het; 或R 1a和R 1b一起限定具有3-6个环原子的饱和环胺; R2a和R2b独立地为H,卤素,C1-C4烷基,C1-C4卤代烷基或C1-C4烷氧基,或R2a和R2b与它们所连接的碳原子一起形成C 3 -C 6环烷基; R3是支链C 5 -C 10烷基链,C 2 -C 4卤代烷基或-CH 2 C 3 -C 7环烷基; R 4是C 1 -C 6烷基,C 1 -C 6卤代烷基,C 1 -C 6烷基氨基或C 1 -C 6二烷基氨基; 用于预防或治疗以组织蛋白酶S不适当表达或活化为特征的病症。
-
公开(公告)号:US20030143714A1
公开(公告)日:2003-07-31
申请号:US10273577
申请日:2002-10-18
申请人: Medivir UK Ltd.
IPC分类号: G06F019/00 , G01N033/48 , G01N033/50 , C12N009/64
CPC分类号: C12N9/6472 , C07K2299/00 , G16B15/00 , G16B20/00
摘要: The invention relates to the X-ray crystal structure of a cathepsin S mutant. The invention further relates to an apparatus programmed with one or more of the structure coordinates of the cathepsin S binding pockets, wherein said apparatus is capable of displaying a three-dimensional representation of that binding pocket.
摘要翻译: 本发明涉及组织蛋白酶S突变体的X射线晶体结构。 本发明还涉及一种利用组织蛋白酶S结合口袋的结构坐标中的一个或多个进行编程的装置,其中所述装置能够显示该装订袋的三维表示。
-
公开(公告)号:US20150025250A1
公开(公告)日:2015-01-22
申请号:US14504419
申请日:2014-10-02
申请人: MEDIVIR UK LTD
发明人: Susana AYESA , Urszula GRABOWSKA , Ellen HEWITT , Daniel JONSSON , Bjorn KLASSON , Pia KAHNBERG , Stina LUNDGREN , Jan TEJBRANT , Daniel WIKTELIUS
IPC分类号: C07D233/61 , C07C231/12 , C07C235/80
CPC分类号: C07D233/61 , A61K38/55 , C07C231/12 , C07C235/80 , C07C237/22 , C07C271/22 , C07C275/18 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07D213/81 , C07D233/60 , C07D277/56 , C07D305/08 , C07K5/06034 , C07K5/0606 , C07K5/06078 , C07K5/06139
摘要: Compounds of the formula I wherein R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a C5-C10 alkyl, optionally substituted with 1-3 substituents independently selected from halo, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy; or R3 is a C2-C4alkyl chain with at least 2 chloro or 3 fluoro substituents; or R3 is C3-C7cycloalkylmethyl, optionally substituted with 1-3 substituents independently selected from C1-C4alkyl, halo, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy; R4 is C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkylamino, C1-C6dialkylamino or; R4 is Het or Carbocyclyl, either of which is optionally substituted with 1-3 substituents R4 is Het, carbocyclyl, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy or C1-C6haloalkoxy; n is 1, 2 or 3; for the use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.
摘要翻译: 其中R 2a和R 2b独立地是H,卤素,C 1 -C 4烷基,C 1 -C 4卤代烷基或C 1 -C 4烷氧基或R 2a和R 2b与它们所连接的碳原子一起形成C 3 -C 6环烷基的式I化合物; R3是任选地被1-3个独立地选自卤素,C 1 -C 4卤代烷基,C 1 -C 4烷氧基,C 1 -C 4卤代烷氧基的取代基取代的C 5 -C 10烷基; 或R3是具有至少2个氯或3个氟取代基的C 2 -C 4烷基链; 或R3是C3-C7环烷基甲基,任选地被1-3个独立地选自C 1 -C 4烷基,卤素,C 1 -C 4卤代烷基,C 1 -C 4烷氧基,C 1 -C 4卤代烷氧基的取代基取代; R 4是C 1 -C 6烷基,C 1 -C 6卤代烷基,C 1 -C 6烷氧基,C 1 -C 6卤代烷氧基,C 1 -C 6烷基氨基,C 1 -C 6二烷基氨基或 R 4是Het或碳环基,其任一个任选被1-3个取代基取代,R 4是Het,碳环基,C 1 -C 6烷基,C 1 -C 6卤代烷基,C 1 -C 6烷氧基或C 1 -C 6卤代烷氧基; n为1,2或3; 用于预防或治疗以组织蛋白酶S的不适当表达或活化为特征的病症。
-
公开(公告)号:US08859605B2
公开(公告)日:2014-10-14
申请号:US13514760
申请日:2010-12-10
申请人: Susana Ayesa , Peter Carlqvist , Karolina Ersmark , Urszula Grabowska , Ellen Hewitt , Daniel Jonsson , Pia Kahnberg , Bjorn Klasson , Peter Lind , Lourdes Oden , Kevin Parkes , Daniel Wiktelius
发明人: Susana Ayesa , Peter Carlqvist , Karolina Ersmark , Urszula Grabowska , Ellen Hewitt , Daniel Jonsson , Pia Kahnberg , Bjorn Klasson , Peter Lind , Lourdes Oden , Kevin Parkes , Daniel Wiktelius
IPC分类号: C07C271/22 , C07D405/12 , C07D231/40 , C07D277/46
CPC分类号: C07K5/06078 , A61K38/05 , C07C271/22 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07D231/40 , C07D277/46 , C07D405/12 , C07K5/06034 , C07K5/0606 , C07K5/06139
摘要: Compounds of the formula I wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10 alkyl chain, C2-C4haloalkyl or —CH2C3-C7 cycloalkyl; R4 is C1-C6alkyl, C1-C6haloalkyl, C1-C6alkylamino or C1-C6dialkylamino; for use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.
摘要翻译: 式Ⅰ化合物,其中R1a是H; 并且R 1b是C 1 -C 6烷基,碳环或Het; 或R 1a和R 1b一起限定具有3-6个环原子的饱和环胺; R2a和R2b独立地为H,卤素,C1-C4烷基,C1-C4卤代烷基或C1-C4烷氧基,或R2a和R2b与它们所连接的碳原子一起形成C 3 -C 6环烷基; R3是支链C 5 -C 10烷基链,C 2 -C 4卤代烷基或-CH 2 C 3 -C 7环烷基; R 4是C 1 -C 6烷基,C 1 -C 6卤代烷基,C 1 -C 6烷基氨基或C 1 -C 6二烷基氨基; 用于预防或治疗以组织蛋白酶S不适当表达或活化为特征的病症。
-
公开(公告)号:US20130172232A1
公开(公告)日:2013-07-04
申请号:US13704441
申请日:2011-06-16
申请人: Susana Ayesa , Urszula Grabowska , Ellen Hewitt , Daniel Jonsson , Bjorn Klasson , Pia Kahnberg , Stina Lundgren , Jan Tejbrant , Daniel Wiktelius
发明人: Susana Ayesa , Urszula Grabowska , Ellen Hewitt , Daniel Jonsson , Bjorn Klasson , Pia Kahnberg , Stina Lundgren , Jan Tejbrant , Daniel Wiktelius
CPC分类号: C07D233/61 , A61K38/55 , C07C231/12 , C07C235/80 , C07C237/22 , C07C271/22 , C07C275/18 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07D213/81 , C07D233/60 , C07D277/56 , C07D305/08 , C07K5/06034 , C07K5/0606 , C07K5/06078 , C07K5/06139
摘要: Compounds of the formula I wherein R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a C5-C10 alkyl, optionally substituted with 1-3 substituents independently selected from halo, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy; or R3 is a C2-C4alkyl chain with at least 2 chloro or 3 fluoro substituents; or R3 is C3-C7cycloalkylmethyl, optionally substituted with 1-3 substituents independently selected from C1-C4alkyl, halo, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy; R4 is C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkylamino, C1-C6dialkylamino or; R4 is Het or Carbocyclyl, either of which is optionally substituted with 1-3 substituents R4 is Het, carbocyclyl, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy or C1-C6haloalkoxy; n is 1, 2 or 3; for the use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.
-
公开(公告)号:US08859505B2
公开(公告)日:2014-10-14
申请号:US13704441
申请日:2011-06-16
申请人: Susana Ayesa , Urszula Grabowska , Ellen Hewitt , Daniel Jonsson , Bjorn Klasson , Pia Kahnberg , Stina Lundgren , Jan Tejbrant , Daniel Wiktelius
发明人: Susana Ayesa , Urszula Grabowska , Ellen Hewitt , Daniel Jonsson , Bjorn Klasson , Pia Kahnberg , Stina Lundgren , Jan Tejbrant , Daniel Wiktelius
IPC分类号: C07K14/81 , C07D233/60 , C07K5/065 , C07C271/22 , C07D277/56 , A61K38/55 , C07D305/08 , C07K5/062 , C07C275/18 , C07K5/078 , C07C237/22 , C07D213/81
CPC分类号: C07D233/61 , A61K38/55 , C07C231/12 , C07C235/80 , C07C237/22 , C07C271/22 , C07C275/18 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07D213/81 , C07D233/60 , C07D277/56 , C07D305/08 , C07K5/06034 , C07K5/0606 , C07K5/06078 , C07K5/06139
摘要: Compounds of the formula I wherein R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a C5-C10 alkyl, optionally substituted with 1-3 substituents independently selected from halo, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy; or R3 is a C2-C4alkyl chain with at least 2 chloro or 3 fluoro substituents; or R3 is C3-C7cycloalkylmethyl, optionally substituted with 1-3 substituents independently selected from C1-C4alkyl, halo, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy; R4 is C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkylamino, C1-C6dialkylamino or; R4 is Het or Carbocyclyl, either of which is optionally substituted with 1-3 substituents R4 is Het, carbocyclyl, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy or C1-C6haloalkoxy; n is 1, 2 or 3; for the use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.
摘要翻译: 其中R 2a和R 2b独立地是H,卤素,C 1 -C 4烷基,C 1 -C 4卤代烷基或C 1 -C 4烷氧基或R 2a和R 2b与它们所连接的碳原子一起形成C 3 -C 6环烷基的式I化合物; R3是任选地被1-3个独立地选自卤素,C 1 -C 4卤代烷基,C 1 -C 4烷氧基,C 1 -C 4卤代烷氧基的取代基取代的C 5 -C 10烷基; 或R3是具有至少2个氯或3个氟取代基的C 2 -C 4烷基链; 或R3是C3-C7环烷基甲基,任选地被1-3个独立地选自C 1 -C 4烷基,卤素,C 1 -C 4卤代烷基,C 1 -C 4烷氧基,C 1 -C 4卤代烷氧基的取代基取代; R 4是C 1 -C 6烷基,C 1 -C 6卤代烷基,C 1 -C 6烷氧基,C 1 -C 6卤代烷氧基,C 1 -C 6烷基氨基,C 1 -C 6二烷基氨基或 R 4是Het或碳环基,其任一个任选被1-3个取代基取代,R 4是Het,碳环基,C 1 -C 6烷基,C 1 -C 6卤代烷基,C 1 -C 6烷氧基或C 1 -C 6卤代烷氧基; n为1,2或3; 用于预防或治疗以组织蛋白酶S的不适当表达或活化为特征的病症。
-
公开(公告)号:US20110312964A1
公开(公告)日:2011-12-22
申请号:US13139962
申请日:2009-12-18
申请人: Susana Ayesa , Anna Karin Belfrage , Björn Classon , Urszula Grabowska , Ellen Hewitt , Vladimir Ivanov , Daniel Jönsson , Pia Kahnberg , Peter Lind , Magnus Nilsson , Lourdes Odén , Mikael Pelcman , Horst Wähling
发明人: Susana Ayesa , Anna Karin Belfrage , Björn Classon , Urszula Grabowska , Ellen Hewitt , Vladimir Ivanov , Daniel Jönsson , Pia Kahnberg , Peter Lind , Magnus Nilsson , Lourdes Odén , Mikael Pelcman , Horst Wähling
IPC分类号: A61K31/5377 , C07D265/30 , C07D413/12 , C07D307/68 , C07D405/12 , C07C237/52 , C07C311/46 , C07C271/24 , A61K31/415 , A61K31/5375 , A61K31/341 , A61K31/18 , A61K31/166 , A61K31/4965 , A61P25/00 , A61P19/02 , A61P11/06 , A61P9/10 , A61P29/00 , A61P11/00 , A61P17/06 , C07D231/40
CPC分类号: C07C311/21 , C07C237/24 , C07C271/24 , C07C2601/02 , C07C2601/04 , C07C2601/06 , C07C2601/08 , C07D207/34 , C07D213/40 , C07D213/71 , C07D231/14 , C07D231/40 , C07D239/80 , C07D241/24 , C07D277/36 , C07D277/56 , C07D295/215 , C07D307/68 , C07D307/85 , C07D401/12 , C07D403/12 , C07D405/12 , C07D417/12
摘要: Compounds of the formula I whereinR1a is H; and R1b is C1-C6 alkyl, Carbocyclyl or Het; orR1a and R1b together define a saturated cyclic amine with 3-6 ring atoms;R2a and R2b are H, halo, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy; orR2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl;R3 is a branched C5-C10alkyl chain, C2-C4haloalkyl or C3-C7cycloalkylmethyl,R4 is Het, Carbocyclyl,optionally substituted as defined in the specification and pharmaceutically acceptable salts,hydrates and N-oxides thereof; are inhibitors of cathepsin S and have utility in the treatment of psoriasis, autoimmune disorders and other disorders such as asthma, arteriosclerosis, COPD and chronic pain
摘要翻译: 式Ⅰ化合物,其中R1a是H; 并且R 1b是C 1 -C 6烷基,碳环或Het; 或R 1a和R 1b一起限定具有3-6个环原子的饱和环胺; R2a和R2b是H,卤素,C1-C4烷基,C1-C4卤代烷基,C1-C4烷氧基; 或R 2a和R 2b与它们所连接的碳原子一起形成C 3 -C 6环烷基; R3是支链C 5 -C 10烷基链,C 2 -C 4卤代烷基或C 3 -C 7环烷基甲基,R 4是Het,碳环基,如本说明书中所定义的任选取代,及其药学上可接受的盐,水合物和N-氧化物; 是组织蛋白酶S的抑制剂,并且可用于治疗牛皮癣,自身免疫性疾病和其它疾病如哮喘,动脉硬化,COPD和慢性疼痛
-
公开(公告)号:US20120309673A1
公开(公告)日:2012-12-06
申请号:US13514758
申请日:2010-12-10
申请人: Susana Ayesa , Karolina Ersmark , Urszula Grabowska , Ellen Hewitt , Daniel Jönsson , Pia Kahnberg , Björn Klasson , Peter Lind , Stina Lundgren , Lourdes Odén , Kevin Parkes , Daniel Wiktelius
发明人: Susana Ayesa , Karolina Ersmark , Urszula Grabowska , Ellen Hewitt , Daniel Jönsson , Pia Kahnberg , Björn Klasson , Peter Lind , Stina Lundgren , Lourdes Odén , Kevin Parkes , Daniel Wiktelius
IPC分类号: A61K38/05 , A61P19/02 , A61P25/00 , C07D241/04 , A61P9/00 , C07D233/48 , C07C271/20 , C07D261/14 , C07D231/40 , A61P11/06
CPC分类号: C07K5/06078 , A61K38/05 , C07C271/22 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07D231/40 , C07D277/46 , C07D405/12 , C07K5/06034 , C07K5/0606 , C07K5/06139
摘要: Compounds of Formula II wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10 alkyl chain, C2-C4haloalkyl or —CH2C3-C7 cycloalkyl; R4′ is C1-C6alkyl, C1-C6haloalkyl or oxetany-3-yl. for use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.
摘要翻译: 式II的化合物,其中R 1a是H; 并且R 1b是C 1 -C 6烷基,碳环或Het; 或R 1a和R 1b一起限定具有3-6个环原子的饱和环胺; R2a和R2b独立地为H,卤素,C1-C4烷基,C1-C4卤代烷基或C1-C4烷氧基,或R2a和R2b与它们所连接的碳原子一起形成C 3 -C 6环烷基; R3是支链C 5 -C 10烷基链,C 2 -C 4卤代烷基或-CH 2 C 3 -C 7环烷基; R 4'是C 1 -C 6烷基,C 1 -C 6卤代烷基或氧杂环丁烷-3-基。 用于预防或治疗以组织蛋白酶S不适当表达或活化为特征的病症。
-
-
-
-
-
-
-
-
-